Switzerland-based BioVersys, a multi-asset, clinical stage biopharmaceutical company focusing on R&D of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, is said to be planning an…
Switzerland: BioVersys planning IPO in Q1
…
…






